Pilot study shows roflumilast improves memory activity in schizophrenia, suggesting cognitive treatment potential.
These changes provide preliminary support for a cerebral mechanism of action of roflumilast, which includes modulation of brain regions involved in memory known to be impaired in patients with schizophrenia. This data supports existing findings suggesting roflumilast has the potential to be an effective treatment for cognitive impairments in schizophrenia.
No takes yet. Share an insight, caveat, or question.
Stanoch et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: